Opus Genetics IRD Increase (Decrease) in Contract Assets and Unbilled Receivables
Increase (Decrease) in Contract Assets and Unbilled Receivables at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept ird:IncreaseDecreaseInContractAssetsAndUnbilledReceivables.
The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's increase (decrease) in contract assets and unbilled receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's increase (decrease) in contract assets and unbilled receivables?
- Opus Genetics (IRD) reported increase (decrease) in contract assets and unbilled receivables of -$186K in Q1 2026.
- How has Opus Genetics's increase (decrease) in contract assets and unbilled receivables changed year-over-year?
- Opus Genetics's increase (decrease) in contract assets and unbilled receivables increased by 65.2% year-over-year, from -$534K to -$186K.
- What does increase (decrease) in contract assets and unbilled receivables mean?
- Tracks the change in assets recognized for revenue earned but not yet billed to customers under existing contracts. For a clinical-stage company, this may relate to milestone payments or collaborative research agreements. It serves as an indicator of the timing of cash inflows relative to the recognition of performance obligations.